Andere Sprachen Viridian Therapeutics, Inc.

Aktien

A2QMUH

US92790C1045

VRDN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 23.04.2024			% 5 Tage	% 1. Jan.
14.25 ^USD	-0.35%		-5.50%	-34.57%

21.03.	VIRIDIAN THERAPEUTICS, INC. : B. Riley bekräftigt seine Kaufempfehlung	ZM
28.02.	VIRIDIAN THERAPEUTICS, INC. : Bewertung von Wedbush kaufen	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Foghorn Therapeutics Names Kristian Humer CFO	16.04.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.04.
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29.03.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.03.
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05.03.
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	27.02.
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	19.02.
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16.02.
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	16.02.
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	16.02.
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	07.02.
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06.02.
Viridian Therapeutics Prices Common Stock Offering at $21 per Share	18.01.
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock	18.01.
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours	17.01.
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock	17.01.
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Viridian Therapeutics, Inc.

Aktien

A2QMUH

US92790C1045

VRDN

Andere Sprachen

Filter